Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
GH Research PLC
US$160m

Transaction Overview:

GH Research PLC (the “Company”) (Nasdaq:GHRS), priced its $160 million upsized initial public offering on June 24, 2021 at a price of $16 per share. The Company issued 10,000,000 shares of common stock. In addition, GH Research has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 common shares at the initial public offering price, less underwriting discounts and commissions.

Company Overview:
​​​​​​​
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

Lead Transaction Banker

More like this

Definitive Healthcare
US$483m
September 2021

Definitive Healthcare

Co-Manager (IPO)
Voluntis S/A
September 2021

Voluntis S/A

Financial Advisor
Health Catalyst Inc.
US$224m
August 2021

Health Catalyst Inc.

Co-Manager (Follow-on)